Serial entrepreneur and investor focused on fintech, payments and enterprise software. Nitin Kumbhani has founded and scaled multiple startups, led product and go-to-market teams, and participated in venture rounds and M&A. Combines operator-to-investor experience, serves on early-stage boards, sources deals in seed to Series A, and advises founders on growth and fundraising.
Serial entrepreneur and investor focused on fintech, payments and enterprise software. Nitin Kumbhani has founded and scaled multiple startups, led product and go-to-market teams, and participated in venture rounds and M&A. Combines operator-to-investor experience, serves on early-stage boards, sources deals in seed to Series A, and advises founders on growth and fundraising.
Operator-led, founder-first investment approach prioritizing early-stage fintech, payments and enterprise software opportunities where product-market fit and go-to-market leverage are evident. Focuses capital on seed to Series A rounds with concentrated, conviction-weighted allocations and explicit follow-on reserves to support scaling through growth inflection points. Underwrites investments through an operator’s lens: product velocity, revenue unit economics, founder execution and customer retention. Time horizon is growth-oriented (3–7 years) with active board engagement, hands-on GTM and fundraising support to de-risk commercialization and accelerate exit optionality.
Operator-led, founder-first investment approach prioritizing early-stage fintech, payments and enterprise software opportunities where product-market fit and go-to-market leverage are evident. Focuses capital on seed to Series A rounds with concentrated, conviction-weighted allocations and explicit follow-on reserves to support scaling through growth inflection points. Underwrites investments through an operator’s lens: product velocity, revenue unit economics, founder execution and customer retention. Time horizon is growth-oriented (3–7 years) with active board engagement, hands-on GTM and fundraising support to de-risk commercialization and accelerate exit optionality.
| Trades 1641 | Longs Won 959/1641 58% | Profit Factor 5.46 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $477,094.94 |
| Average Win $107,791.16 | Best Trade (Mar 31) $13.54M | Sharpe Ratio -11.86 |
| Average Loss -$27,742.53 | Worst Trade (Sep 10) -$1.65M | Z-Score -1.86 (95.8%) |
| Commissions $0 | Avg. Trade Length 8m 3w 1d | Expectancy $51,401.15 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 8,547 | 7,692 | 6,838 | 5,983 | 5,128 | 4,274 | 3,419 | 2,564 | 1,709 | 855 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAPL Apple Inc. | 82,350 | $23.21M | $24.89M | - | $1.68M | 7.22% | -0.872% |
ABBV AbbVie Inc. | 3,530 | $828,185.1 | $878,122.76 | - | $49,937.66 | 6.03% | -0.532% |
ADM Archer-Daniels-Midland Co | 101 | $7,716 | $8,052.73 | - | $336.73 | 4.36% | -0.907% |
ADMA Adma Biologics Inc. | 701 | $5,867 | $6,855.78 | - | $988.78 | 16.85% | -1.262% |
AGX Argan Inc. | 14 | $11,180 | $8,009.4 | - | -$3,170.6 | -28.36% | -1.108% |
ALAB ASTERA LABS INC COMMON STOCK (Ticker: 1ALAB) | 22 | $10,626 | $7,013.6 | - | -$3,612.4 | -34% | +2.183% |
ALB Albemarle Corporation | 49 | $6,616 | $6,288.66 | - | -$327.34 | -4.95% | -0.788% |
ALHC Alignment Healthcare, Inc. | 297 | $7,072 | $4,015.44 | - | -$3,056.56 | -43.22% | +2.424% |
ALKS Alkermes plc | 240 | $11,536.8 | $12,067.2 | - | $530.4 | 4.6% | +2.174% |
ALL Allstate Corporation | 29 | $6,927 | $7,419.36 | - | $492.36 | 7.11% | -2.437% |
ALNY Alnylam Pharmaceuticals Inc | 19 | $5,720 | $4,255.05 | - | -$1,464.95 | -25.61% | +1.243% |
AMD Advanced Micro Devices, Inc. | 2,807 | $986,951.03 | $1.36M | - | $368,633.45 | 37.35% | +1.815% |
AMG Affiliated Managers Group Inc. | 42 | $14,213 | $15,220.8 | - | $1,007.8 | 7.09% | +0.927% |
AMRX Amneal Pharmaceuticals Inc. | 1,965 | $34,014 | $34,701.9 | - | $687.9 | 2.02% | +3.275% |
AMZN Amazon.com Inc | 45,350 | $10.53M | $12.12M | - | $1.59M | 15.11% | -1.833% |
ANRO Alto Neuroscience Inc. | 366 | $9,659 | $10,679.88 | - | $1,020.88 | 10.57% | +1.39% |
APA APA Corporation | 251 | $8,175 | $10,032.47 | - | $1,857.47 | 22.72% | -1.6% |
ARCB ArcBest Corporation | 169 | $24,258 | $23,766.47 | - | -$491.53 | -2.03% | +3.587% |
ARGX argenx SE American Depositary Receipt | 1,049 | $973,231 | $918,924 | - | -$54,307 | -5.58% | +1.302% |
ARMK Aramark | 146 | $8,307 | $8,811.1 | - | $504.1 | 6.07% | -0.198% |